

## HR 5115

U.S. Healthcare Technologies Competitiveness Act of 2006

**Congress:** 109 (2005–2007, Ended)

**Chamber:** House

**Policy Area:** Taxation

**Introduced:** Apr 6, 2006

**Current Status:** Referred to the House Committee on Ways and Means.

**Latest Action:** Referred to the House Committee on Ways and Means. (Apr 6, 2006)

**Official Text:** <https://www.congress.gov/bill/109th-congress/house-bill/5115>

### Sponsor

**Name:** Rep. Hart, Melissa A. [R-PA-4]

**Party:** Republican • **State:** PA • **Chamber:** House

### Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. English, Phil [R-PA-3]	R · PA		Apr 6, 2006
Rep. Weller, Jerry [R-IL-11]	R · IL		Apr 6, 2006
Rep. Ramstad, Jim [R-MN-3]	R · MN		Apr 27, 2006

### Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	Apr 6, 2006

### Subjects & Policy Tags

**Policy Area:**

Taxation

### Related Bills

*No related bills are listed.*

U.S. Healthcare Technologies Competitiveness Act of 2006 - Amends the Internal Revenue Code to provide tax incentives for investment in biomedical research corporations and related entities, by: (1) exempting investors in biomedical research corporations from limitations on net operating losses acquired through stock sales and mergers involving such corporations; (2) permitting a complete offset against the alternative minimum tax for the net operating losses of biomedical research corporations; (3) making permanent and increasing the rates for the tax credit for increasing research activities; (4) allowing tax credits for countermeasures equity investments and research expenses, qualified medical innovation expenses, equity investments in incubational companies, and investment in qualified biotechnology zone bonds; (5) accelerating eligibility for the tax credit for orphan drug expenses; (6) allowing expensing of biotechnology science park property and medical research equipment; (7) allowing deferral of the tax on gain from the sale of stock in a biomedical research corporation; (8) increasing the tax deductibility of capital losses on the sale of stock in biomedical research corporations; and (9) modifying passive loss deduction rules and S corporation shareholder requirements for biomedical research corporations.

### **Actions Timeline**

---

- **Apr 6, 2006:** Introduced in House
- **Apr 6, 2006:** Introduced in House
- **Apr 6, 2006:** Referred to the House Committee on Ways and Means.